Lectins

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

Retrieved on: 
Friday, July 9, 2021

Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer.

Key Points: 
  • Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer.
  • Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
  • Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

BBH Names Laura Cona as Head of Growth

Retrieved on: 
Monday, June 28, 2021

NEW YORK, June 28, 2021 /PRNewswire/ -- BBH announced today FCB New York's Laura Dunn Cona will serve as the agency's newly appointed Head of Growth.

Key Points: 
  • NEW YORK, June 28, 2021 /PRNewswire/ -- BBH announced today FCB New York's Laura Dunn Cona will serve as the agency's newly appointed Head of Growth.
  • Cona will report to BBH NY President Amani Duncan.
  • "Today's appointment demonstrates BBH's commitment to an ambitious growth agenda and attracting the best talent in the business," said Duncan.
  • "Rafa, Tom and I are looking forward to working closely with Laura to continue building upon our incredible momentum."

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update

Retrieved on: 
Monday, May 17, 2021

b"NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2021.

Key Points: 
  • b"NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2021.
  • These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the\xc2\xa0U.S.
  • The study suggests combination therapy with belapectin results in a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA\xc2\xae) alone.
  • The paper describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon.

Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT

Retrieved on: 
Wednesday, April 28, 2021

Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg\xc2\xae or, if approved by the FDA, Vor\xe2\x80\x99s in-licensed CD33 chimeric antigen receptor T-cell (CAR-T) therapy candidate, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures.

Key Points: 
  • Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg\xc2\xae or, if approved by the FDA, Vor\xe2\x80\x99s in-licensed CD33 chimeric antigen receptor T-cell (CAR-T) therapy candidate, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures.
  • The words \xe2\x80\x9cbelieve,\xe2\x80\x9d \xe2\x80\x9ccontinue,\xe2\x80\x9d \xe2\x80\x9ccould,\xe2\x80\x9d \xe2\x80\x9cestimate,\xe2\x80\x9d \xe2\x80\x9cexpect,\xe2\x80\x9d \xe2\x80\x9cintend,\xe2\x80\x9d \xe2\x80\x9cmay,\xe2\x80\x9d \xe2\x80\x9cplan,\xe2\x80\x9d \xe2\x80\x9cpotential,\xe2\x80\x9d \xe2\x80\x9cproject,\xe2\x80\x9d \xe2\x80\x9cshould,\xe2\x80\x9d \xe2\x80\x9ctarget,\xe2\x80\x9d \xe2\x80\x9cwill,\xe2\x80\x9d \xe2\x80\x9cwould,\xe2\x80\x9d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
  • Forward-looking statements in this press release include statements regarding Vor\xe2\x80\x99s (the Company) platform\xe2\x80\x99s potential to treat patients suffering from acute myeloid leukemia.
  • The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Galectin Therapeutics to Present at 4th Global NASH Congress

Retrieved on: 
Tuesday, April 27, 2021

b'NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.\nOn Thursday, April 29th, Dr. Boudes will review Galectin Therapeutics\xe2\x80\x99 scientific and clinical activities in NASH cirrhosis, followed by a Q&A session.

Key Points: 
  • b'NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.\nOn Thursday, April 29th, Dr. Boudes will review Galectin Therapeutics\xe2\x80\x99 scientific and clinical activities in NASH cirrhosis, followed by a Q&A session.
  • Gal-3, a glycan binding protein, orchestrates liver inflammation and fibrosis in NASH cirrhosis.
  • Galectin is conducting a seamless, adaptive, double-blind, randomized, placebo controlled phase 2b/3 global study in patients with portal hypertension due to NASH cirrhosis who have not yet developed varices.
  • The primary outcome is the development of esophageal varices at 18 months.\nThe annual Global NASH Congress, usually held in London, will be taking place virtually on April 28 and 29, 2021.

Thinking about buying stock in Galectin Therapeutics, Moleculin Biotech, Microvision, Nikola Corp, or Ardelyx?

Retrieved on: 
Wednesday, April 14, 2021

b"InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.

Key Points: 
  • b"InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-g...\n"

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 31, 2021

NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020.

Key Points: 
  • NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020.
  • Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, I am very encouraged by the progress achieved in fiscal 2020, and remain extremely optimistic for 2021.
  • Additionally, I believe this breadth of talent reinvigorated Galectin and placed the Company in a position to monetize our assets.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

Retrieved on: 
Tuesday, March 23, 2021

Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.
  • The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.
  • The pulmonary and critical care investigators leading the I-SPY COVID Trial uniformly endorsed narsoplimab and made it a high-priority candidate for the trial.
  • Narsoplimab is Omeros lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement.

OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy

Retrieved on: 
Monday, March 8, 2021

Galectin-3 acts to maintain tumor growth, in part, by supporting the generation of suppressive macrophages and inhibiting T cell function.

Key Points: 
  • Galectin-3 acts to maintain tumor growth, in part, by supporting the generation of suppressive macrophages and inhibiting T cell function.
  • This is very significant research, noted Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.
  • Preliminary results indicated that the combination of Keytruda and belapectin may improve the efficacy of this potent PD-1 inhibitor while also improving its tolerance.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021

NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

Key Points: 
  • NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.
  • The presentation will be available for on-demand listening beginning March 9, 2021 at 7:00 am (EST) and archived for 90 days.
  • Galectin Therapeuticsis dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02